Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)

Adjuvant Chemotherapy Clinical Trial

— EPAC1  

Official title:

Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03199989
• Other study ID #: PKUCH-C01
• Status: Recruiting
• Phase: Phase 3
• Start date: June 1, 2017
• Est. completion date: July 31, 2024

Study information

• Verified date: March 2020
• Source: Beijing Cancer Hospital
• Contact: Pengju Chen, M.D.
• Phone: +8613811403082
• Email: pengjuchen[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to design a prospective randomized clinical trial to explore whether postoperative adjuvant chemotherapy may provide survival benefit for stage II colon cancer patients with high risk factors.Therefore the investigators can provide high level clinical evidence of indications for patients with colon cancer with stage II colon cancer.

Description:

The most controversial of adjuvant chemotherapy for colon cancer is whether stage II colon cancer should receive adjuvant chemotherapy or not. Because of the absolute little benefit of adjuvant chemotherapy after curative resection of stage II colon cancer，NCCN and ESMO guidelines do not recommend routine adjuvant chemotherapy for patients with stage II colon cancer unless combined with high risk factors.

Currently，most studies about stage II colon cancer with high risk factors were retrospective. Some suggested that patients with stage II colon cancer can benefit from adjuvant chemotherapy, however, more got the negative conclusions.

The study was designed as a multicenter, prospective, randomized, controlled trial.Patients who agreed to participate in the study would be randomly assigned to a treatment group of adjuvant chemotherapy or observation with 50% chance by a central randomization system determined by the computer program.

After a follow up of at least 3 years, the disease free survival of the two groups will be compared.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1254
• Est. completion date: July 31, 2024
• Est. primary completion date: July 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. aged 18 to 75 years;

2. pathologically confirmed adenocarcinoma of the colon

3. after curative resection pathological stage was T3-4N0M0;

4. with at least one of the following factors:

1. T4 staging

2. lymph nodes number less than 12

3. poor differentiation (except MSI-H)

4. LVI or PNI

5. obstruction or perforation

6. Elevated preoperative serum CEA

5. ECOG Performance status 0-1

6. no evidence of distant metastases

7. no preoperative chemotherapy or chemoradiation therapy

8. ANC > 1.5 cells/mm3, HGB > 10.0 g/dL, PLT > 100,000/mm3, total bilirubin = 1.5 xULN, AST= 3 x ULN, ALT = 3 x ULN.

9. Patients must read, agree to, and sign a statement of Informed Consent prior to participation in this study.

Exclusion Criteria:

1. combined with other cancer

2. Creatinine level greater than 1.5 times the upper limit of normal.

3. Patients who have received preoperative chemotherapy or chemoradiotherapy.

4. Patients with a history of a prior malignancy within the past 5 years.

5. Women who are pregnant or breast-feeding.

6. patients may not complete the whole schedule of chemotherapy

7. Patients with any other concurrent medical or psychiatric condition or disease which would make them inappropriate candidates for entry into this study.

Related Conditions & MeSH terms

• Adjuvant Chemotherapy
• Colonic Neoplasms

Intervention

Drug:
• CapeOX(Capecitabine+Oxaliplatin)
Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX(Capecitabine+Oxaliplatin)for 6 months

Other:
• Observation
Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation

Locations

Country	Name	City	State
China	Beijing cancer hospital	Beijing

Sponsors (3)

Lead Sponsor	Collaborator
Beijing Cancer Hospital	Peking Union Medical College Hospital, Peking University People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	3-year disease free survival	Disease free survival was defined as the duration after local recurrence or metastasis were found after surgery. Metastasis of any distant organs such as liver, lung, ovary,bone and peritoneum were defined by CT.	At least 3 years after the last patient enrolled
Secondary	3-year overall survival	Overall survival was defined as the duration from randomization to death from any cause	At least 3 years after the last patient enrolled
Secondary	Rate of metastasis	Rate of metastasis in different groups	At least 3 years after the last patient enrolled
Secondary	Relationship between high risk factors and survival	All the high risk factors enrolled in this study will be analyzed one by one to investigate the relationship between high risk factors and survival.	At least 3 years after the last patient enrolled
Secondary	Major adverse events	Toxic reaction in the chemotherapy group.Adverse events will be graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0	At least 1 years after the last patient enrolled